Clinical significance of human leukocyte antigen loss and melanoma-associated antigen 4 expression in smokers of non-small cell lung cancer patients

International Journal of Clinical Oncology

Volumn 18, Issue 6, 2013, Pages 997-1004

  Baba, Tetsuro ^a   Shiota, Hironobu ^a   Kuroda, Koji ^a   Shigematsu, Yoshiki ^a   Ichiki, Yoshinobu ^a   Uramoto, Hidetaka ^a   Hanagiri, Takeshi ^a   Tanaka, Fumihiro ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Cancer testis antigen; HLA class I; Non small cell lung cancer; Smoking; Tumor immunology

Indexed keywords

HLA ANTIGEN CLASS 1;

AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAGE A4 GENE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOKING HABIT; SURVIVAL RATE; TUMOR GENE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; SMOKING; SURVIVAL ANALYSIS;

EID: 84891486289     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0491-8     Document Type: Article

References (32)

1. Hanagiri T, Baba T, So T et al (2010) Time trends of surgical outcome in patients with non-small cell lung cancer. J Thorac Oncol 5:825-829
2. Small EJ, Schellhammer PF, Higano CS et al (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24:3089-3094
3. Vansteenkiste J, Zielinski M, Linder A et al (2007) Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol Suppl 25:398s
4. Tyagi P, Mirakhur B (2009) MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 10:371-374
5. van der Bruggen P, Traversari C, Chomez P et al (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1647
6. Shigematsu Y, Hanagiri T, Shiota H et al (2010) Clinical significance of cancer/testis antigens expression in patients with non-small cell lung cancer. Lung Cancer 68:105-110
7. So T, Takenoyama M, Mizukami M et al (2005) Haplotype loss of HLA-class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res 65:5945-5952
8. Baba T, Hanagiri T, Takenoyama M et al (2010) Identification of a lung cancer antigen evading CTL attack due to loss of human leukocyte antigen (HLA) class I expression. Cancer Sci 101:2115-2120
9. Baba T, Hanagiri T, Ichiki Y et al (2007) Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B. Cancer Sci 98:1795-1802
10. Redondo M, Concha A, Oldiviela R et al (2009) Expression of HLA class I and II antigens in bronchogenic carcinomas: its relationship to cellular DNA content and clinical-pathological parameters. Cancer Res 51:4948-4954
11. Passlick B, Izbicki JR, Simmel S et al (1994) Expression of major histocompatibility class I and class II antigens and intercellular adhesion molecule-1 on operable non-small cell lung carcinomas: frequency and prognostic significance. Eur J Cancer 30A:376-381
12. Ramnath N, Tan D, Li Q et al (2005) Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? Cancer Immunol Immunother 27:1-9
13. Kikuchi E, Yamazaki K, Torigoe T et al (2007) HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci 98:1424-1430
14. Shimokawa H, Uramoto H, Onitsuka T et al (2011) TS expression predicts postoperative recurrence in adenocarcinoma of the lung. Lung Cancer 72:360-364
15. Hanagiri T, Shigematsu Y, Kuroda K et al (2012) Prognostic implications of human leukocyte antigen class I expression in patients who underwent surgical resection for non-small-cell lung cancer. J Surg Res (Epub ahead of print)
16. Yoshino I, Fukuyama S, Kameyama T et al (2003) Detection of loss of heterozygosity by high-resolution fluorescent system in non-small cell lung cancer: association of loss of heterozygosity with smoking and tumor progression. Chest 123:545-550
17. Zienolddiny S, Haugen A, Su L et al (2011) Cigarette smoking increases copy number alterations in nonsmall-cell lung cancer. Proc Natl Acad Sci USA 108:16345-16350
18. Hays LE, Zodrow DM, Yates JE et al (2008) Cigarette smoke induces genetic instability in airway epithelial cells by suppressing FANCD2 expression. Br J Cancer 98:1653-1661
19. Hirao T, Nelson HH, Ashok TD et al (2001) Tobacco smoke-induced DNA damage and an early age of smoking initiation induce chromosome loss at 3p21 in lung cancer. Cancer Res 61:612-615
20. Iniesta P, González-Quevedo R, Morán A et al (2004) Relationship between 3p deletions and telomerase activity in non-small-cell lung cancer: prognostic implications. Br J Cancer 90:1983-1988
21. Madjd Z, Spendlove I, Pinder SE et al (2005) Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 117:248-255
22. Watson NF, Ramage JM, Madjd Z et al (2006) Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer 118:6-10
23. Hanagiri T, Sugio K, Mizukami M et al (2008) Significance of smoking as a postoperative prognostic factor in patients with non-small cell lung cancer. J Thorac Oncol 3:1127-1132
24. Chaux P, Luiten R, Demotte N et al (1999) Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol 163:2928-2936
25. Shirakura Y, Mizuno Y, Wang L et al (2012) TCR gene therapy targeting MAGE-A4 inhibits human tumor growth in NOD/SCID/γc(null) mice. Cancer Sci 103:17-25
26. Kim YD, Park HR, Song MH et al (2012) Pattern of cancer/testis antigen expression in lung cancer patients. Int J Mol Med 29:656-662
27. Liu F, Killian JK, Yang M et al (2010) Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate. Oncogene 29:3650-3664
28. Scanlan MJ, Gure AO, Jungbluth AA et al (2002) Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188:22-32
29. De Smet C, Lurquin C, Lethe B et al (1999) DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 19:7327-7335
30. De Smet C, De Backer O, Faraoni I et al (1996) The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci USA 93:7149-7153
31. Liu F, Killian JK, Yang M et al (2010) Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate. Oncogene 29:3650-3664
32. Roos-Engstrand E, Pourazar J, Behndig AF et al (2010) Cytotoxic T cells expressing the co-stimulatory receptor NKG2 D are increased in cigarette smoking and COPD. Respir Res 11:128